Prescription medicine
Carboprost Brand names: Hemabate
Carboprost (Hemabate) is a prescription medicine with an FDA approval on record since 1979. FDA's NDC Directory lists it from 22 generic labelers.
- Generic listed
- Boxed warning
Check it at the source: the carboprost FDA label on DailyMed (effective March 30, 2026, Pharmacia & Upjohn Company LLC); the NDA 17989 record on Drugs@FDA; every carboprost label on DailyMed.
Highlights of the record
FDA label of March 30, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
HEMABATE Sterile Solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. HEMABATE should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.
Used for
From the label: indications and usageHEMABATE Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1.
Forms and strengths
Injection (solution); solution; injection.
On the market
- Earliest approval on file
- January 9, 1979 Hemabate, Pfizer; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 13 first July 2, 2019; 12 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 23 of which 22 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 712 through July 30, 2026
What is carboprost used for?
From the label: indications and usageHEMABATE Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. […]
FDA pharmacologic class: Prostaglandin Analog.
Source: FDA drug label (Hemabate), NDA017989 (Pfizer), as published by Pharmacia & Upjohn Company LLC, effective March 30, 2026 (SPL set 3d282998-ff0c-480a-bd80-155606ef0a65), via openFDA; the full label on DailyMed
Is there a generic for carboprost (Hemabate)?
The FDA approved the first generic carboprost on July 2, 2019. 13 generic applications are approved; 12 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists carboprost from 22 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1979 earliest approval on file
- 2019 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the carboprost label say about other medicines?
The carboprost label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Tromethamine | boxed warning | WARNINGS HEMABATE Sterile Solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. |
Source: FDA drug label (Hemabate), NDA017989 (Pfizer), as published by Pharmacia & Upjohn Company LLC, effective March 30, 2026 (SPL set 3d282998-ff0c-480a-bd80-155606ef0a65), via openFDA; the full label on DailyMed
What do FAERS reports show for carboprost?
The FDA Adverse Event Reporting System holds 712 reports that list carboprost among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2 are coded as a death and 74 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other prostaglandin analogs
- the pharmacologic class, with prices and generics
- Carboprost side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other